Elicio Therapeutics (ELTX) Cost of Revenue (2020 - 2021)
Elicio Therapeutics (ELTX) reported Cost of Revenue of $433000.0 for Q4 2021, up 243.65% on a YoY basis from $126000.0 in Q4 2020, and up 243.65% quarter-over-quarter from $126000.0 in Q4 2020.
Elicio Therapeutics (ELTX) Cost of Revenue (2020 - 2021) Analysis & Trends
Elicio Therapeutics has reported Cost of Revenue for 2 years, with the latest figure at $433000.0 in Q4 2021.
- For the quarter ending Q4 2021, Cost of Revenue rose 243.65% year-over-year to $433000.0; the trailing twelve-month figure through Dec 2021 stood at $433000.0 (down 63.61% YoY), and the FY2021 full-year result was $433000.0, down 63.61% from the prior year.
- Cost of Revenue for Q4 2021 stood at $433000.0, up from $126000.0 in the prior quarter.
- The five-year high for Cost of Revenue was $433000.0 in Q4 2021, with the low at $126000.0 in Q4 2020.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | - |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 64.20 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | - |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | 48,670.00 |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 392.80 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 2.05 Mn |
| 10 | Elicio Therapeutics | 70.12 Mn | 55.17 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2021 | 433,000.00 |
| Dec 31, 2021 | 433,000.00 |
| Dec 31, 2020 | 126,000.00 |
| Dec 31, 2020 | 126,000.00 |
| Sep 30, 2020 | 348,000.00 |
| Sep 30, 2020 | 348,000.00 |
| Jun 30, 2020 | 333,000.00 |
| Jun 30, 2020 | 333,000.00 |
| Mar 31, 2020 | 383,000.00 |
| Mar 31, 2020 | 383,000.00 |